Wanbury Limited (WANBURY) AI Stock Analysis

• Market Cap: ₹7.50B
• Dividend Yield: N/A
• Average Volume (3M): 8.26K
• Price to Earnings (P/E): 17.4
• Beta (1Y): 2.10
• Revenue Growth: 12.37%
• EPS Growth: -17.98%
• Country: IN
• Employees: 1,491
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 4.10
• Shares Outstanding: 32,877,000
• 10 Day Avg. Volume: 8,584
• 30 Day Avg. Volume: 8,255
• PEG Ratio: -0.63
• Price to Book (P/B): 14.81
• Price to Sales (P/S): 1.46
• P/FCF Ratio: -38.28
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹257.00
• Price Target Upside: 9.67% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 58 Neutral
• Price Target: ₹257.00 ▲(9.67% Upside)

Wanbury Limited's stock score is primarily influenced by its financial performance, which shows strong revenue growth but is hindered by high leverage and negative cash flow. Technical analysis indicates bearish momentum, and valuation suggests moderate attractiveness. The absence of earnings call and corporate events data limits further insights.

Wanbury Limited Business Overview & Revenue Model

Company Description

Wanbury Limited (WANBURY) is a pharmaceutical company based in India that specializes in the development, manufacturing, and marketing of a diverse range of generic and specialty medicines. The company operates primarily in the healthcare sector, focusing on therapeutic areas such as cardiology, psychiatry, neurology, and gynecology. Wanbury is known for its commitment to quality and innovation, with a portfolio that includes both oral and injectable formulations, catering to the needs of various markets across India and internationally.

How the Company Makes Money

Wanbury generates revenue primarily through the sale of pharmaceutical products, including generics and specialty drugs, to healthcare providers, pharmacies, and distributors. The company has established key revenue streams through its extensive product portfolio and a strong distribution network that allows it to reach a wide customer base. Additionally, Wanbury's revenue is bolstered by strategic partnerships and collaborations with other pharmaceutical firms, which can include joint ventures for research and development, as well as licensing agreements that expand its market reach and product offerings. The company also benefits from export sales, as it supplies its products to international markets, thereby diversifying its income sources and enhancing its overall financial performance.

Wanbury Limited Financial Statement Overview

Summary

Wanbury Limited is on a recovery path with strong revenue growth and improving profitability margins. However, the company faces challenges with high leverage and consistent free cash flow deficits. Continued focus on debt management and cash flow enhancement would be crucial for sustained financial stability.

Income Statement

Wanbury Limited shows a strong recovery in revenue with a noticeable growth rate from 2023 to 2025. The gross profit and EBIT margins have improved, indicating enhanced operational efficiency. However, net profit margin is fluctuating, showing some instability in profitability. Despite this, the overall trend appears positive with EBITDA margins also showing strength.

Balance Sheet

The company's debt-to-equity ratio indicates high leverage which poses a potential risk, but the positive stockholders' equity in 2025 is a significant improvement from previous negative values. The equity ratio is low, indicating a higher reliance on debt, but the return on equity is improving, suggesting better profitability management.

Cash Flow

Operating cash flow has shown improvement with positive trends, though free cash flow remains negative in recent years, highlighting potential liquidity challenges. The operating cash flow to net income ratio is strong, indicating efficient cash management relative to earnings.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	6.30B	6.00B	5.74B	4.98B	5.11B	3.87B
Gross Profit	3.26B	3.05B	2.65B	1.89B	2.04B	1.61B
EBITDA	926.84M	798.13M	985.49M	234.91M	1.13B	204.23M
Net Income	429.83M	305.30M	559.56M	-103.96M	814.74M	-126.06M
Balance Sheet
Total Assets	0.00	4.14B	3.43B	3.04B	3.53B	2.89B
Cash, Cash Equivalents and Short-Term Investments	129.60M	150.63M	34.00M	14.94M	226.56M	101.31M
Total Debt	0.00	1.77B	1.16B	1.09B	1.08B	2.04B
Total Liabilities	-592.72M	3.55B	3.16B	3.36B	3.76B	4.45B
Stockholders Equity	592.72M	592.72M	279.41M	-61.54M	-234.20M	-1.56B
Cash Flow
Free Cash Flow	0.00	-229.26M	-134.45M	71.69M	308.65M	122.53M
Operating Cash Flow	0.00	261.02M	39.78M	197.97M	405.23M	166.81M
Investing Cash Flow	0.00	-511.74M	-166.25M	-88.38M	5.87M	80.44M
Financing Cash Flow	0.00	257.33M	145.53M	-319.91M	-285.85M	-173.85M

Wanbury Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 234.35
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:WANBURY, the sentiment is Negative. The current price of 234.35 is below the 20-day moving average (MA) of 248.71, below the 50-day MA of 260.71, and below the 200-day MA of 255.08, indicating a bearish trend. The MACD of -6.35 indicates Positive momentum. The RSI at 29.93 is Positive, neither overbought nor oversold. The STOCH value of 7.69 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:WANBURY.

Wanbury Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
KILITCH	64 Neutral	₹6.56B	22.02	―	―	37.51%	122.52%
SAKAR	64 Neutral	₹7.72B	39.03	―	―	21.65%	73.16%
KOPRAN	61 Neutral	₹8.18B	23.42	―	1.77%	-1.83%	-41.16%
THEMISMED	61 Neutral	₹11.48B	―	―	0.40%	-6.86%	-118.14%
WANBURY	58 Neutral	₹7.50B	17.40	―	―	12.37%	-17.98%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Wanbury Limited Corporate Events

Wanbury Limited Allots Rs. 25 Crore Debentures to Tata Capital

Wanbury Limited’s Day-to-Day Affairs Committee of the Board of Directors approved the allotment of 250 Unlisted, Secured Redeemable, Non-Convertible Debentures to Tata Capital Limited, amounting to Rs. 25 Crores. This move aims to finance the company’s capital expenditure and working capital requirements, as well as address identified liabilities, potentially strengthening its financial position and operational capabilities.

Wanbury Limited Announces 37th AGM and E-Voting Details

Wanbury Limited has announced the scheduling of its 37th Annual General Meeting (AGM) to be held on September 18, 2025, at Ebony Hall, Hotel Tunga Regenza, Navi Mumbai. The company has provided details about the electronic voting process for shareholders, which will be available from September 15 to September 17, 2025, through Purva Sharegistry. The results of the voting will be declared within 48 hours after the AGM, and the meeting will address both ordinary and special business matters.

Wanbury Limited Announces Key Appointments and Strategic Decisions

Wanbury Limited announced the appointment of Mr. Chandran Krishnamoorthy as a Whole Time Director, effective August 4, 2025. The company also approved its unaudited financial results for the first quarter ending June 30, 2025, and granted 91,500 stock options to employees. Additionally, the company initiated the closure of three foreign subsidiaries, which had not commenced operations, ensuring no impact on its revenue or business.

Wanbury Limited Announces Key Board Decisions and Subsidiary Closures

Wanbury Limited announced several key decisions following its Board of Directors meeting on August 4, 2025. The company approved its unaudited financial results for the first quarter ending June 30, 2025, and granted 91,500 stock options to employees under its Employee Stock Option Plan 2016. Additionally, the reappointment of Mr. Chandran Krishnamurthy as a Whole-time Director for a five-year term was approved, pending shareholder approval. Furthermore, Wanbury Limited initiated the closure of three foreign subsidiaries, which had not commenced operations, ensuring no impact on the company’s revenue or business.